$0.81
12.5%
Price vs. AI Score (Last 150 days)
Data gathered: December 6
Data gathered: December 6
Data Bits
| Data Bits | Value / Change | Benchmark |
|---|---|---|
| Job Posts | 9 0% |
|
| Sentiment | 75 0% |
|
| Webpage traffic | 10,000 -20.6% |
|
| Employee Rating | 70 0% |
|
| Google Adspend | $ N/A | N/A |
| Google Trends | 55 19.6% |
|
| Linkedin Employees | 492 N/A |
|
| Patents | 128 0% |
|
| 4chan Mentions | 0% | N/A |
| Facebook Engagement | 0% | N/A |
| Facebook followers | 1,210 0% | N/A |
| Stocktwits Mentions | 55 -26.7% |
|
| Stocktwits Subscribers | 30,997 0% |
|
| Twitter Followers | 2,190 0% |
|
| News Mentions | 0% |
|
| Reddit Mentions | 0% |
|
| Business outlook | 23 0% |
|
In the news
 |
What Makes Amarin (AMRN) a New Buy StockDecember 5 - Yahoo |
Sarissa Capital Believes Amarin Stock Is Meaningfully Undervalued and Has Increased Its OwnershipDecember 4 - Business Wire |
|
Catalyst Pharmaceuticals Announces Appointment of Michael W. Kalb as Chief Financial Officer and Other Executive PromotionsDecember 3 - GlobeNewswire |
|
Sarissa Capital says Amarin stock undervalued, months after winning proxy contestDecember 3 - Seeking Alpha |
|
12 Health Care Stocks Moving In Monday's After-Market SessionDecember 3 - Benzinga |
|
Sarissa Capital sees Amarin shares as 'meaningfully undervalued', boosting stakeDecember 3 - Thefly.com |
|
About Amarin
Amarin Corporation is an Irish-American biopharmaceutical company founded in 1993 and headquartered in Dublin, Ireland and Bridgewater, New Jersey. The company develops and markets medicines for the treatment of cardiovascular disease. It has developed the drug Vascepa, a prescription grade omega-3 fatty acid.
| Price | $0.81 |
| Target Price | Sign up |
| Market Cap | $294M |
| Dividend Yield | 0.0212 |
| Industry | Biotechnology |
Similar companies
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | |
|---|---|---|---|---|---|
| Q3 '23 | 66M | 70M | 30M | -19M | -21M |
| Q2 '23 | 80M | 84M | 43M | -18M | -23M |
| Q1 '23 | 86M | 86M | 48M | -16M | -17M |
| Q4 '22 | 90M | 95M | 64M | 860,000 | -9M |
| Q3 '22 | 90M | 86M | 63M | -5.1M | -4.5M |
Insider Transactions
| Holt Patrick filed to buy 300,000 shares at $1.1. August 16 '23 |
Read more about Amarin and their earnings, price prediction, job posts, sentiment, webpage traffic, employee rating, google adspend, google trends, linkedin employees, patents, 4chan mentions, facebook engagement, facebook followers, stocktwits mentions, stocktwits subscribers, twitter followers, news mentions, reddit mentions, business outlook.